Connect with us

Government

Schumer marijuana legalization bill finally introduced in Senate

Published

on

Legislation to remove the decades-old federal ban on marijuana was at long last introduced Thursday by Senate Majority Leader Chuck Schumer, and cannabis industry leaders were gleeful over the milestone, even though it’s a long shot that the legalization bill will become law.

Most marijuana lobbyists give Schumer’s Cannabis Administration and Opportunity Act (CAOA) almost zero chance of getting through the Senate, since it would need 60 votes to pass.

But several said it could lend momentum to more incremental reform bills – most notably the SAFE Banking Act, which would allow banks to serve cannabis businesses without fear of federal reprisal.

“It really does increase the chances of something happening,” said Randal Meyer, the executive director of the Global Alliance for Cannabis Commerce (GACC), who said the CAOA might have “an uncorking effect” for marijuana legislation.

Schumer and colleagues including U.S. Sens. Cory Booker of New Jersey and Ron Wyden of Oregon have been working on the 296-page measure mostly behind closed doors since early 2021.

draft of the bill was circulated last year.

“The question today is no longer whether cannabis should be legal – many states have already made that decision on their own initiative. The question is whether cannabis should be subject to the same high regulatory standards that apply to alcohol and tobacco,” Schumer, Booker and Wyden said in a joint statement released Thursday.

According to a synopsis from Schumer’s office, the new bill would:

  • Remove marijuana from the list of federally controlled substances.
  • Allow states to continue taking the lead on regulating the industry but also maintain prohibition in states that have not legalized.
  • Establish a “regulatory regime similar to alcohol and tobacco” from the federal government.

A variety of industry trade groups offered feedback last fall on changes they’d like to see in the measure – including lowering the proposed national marijuana tax rate, which was partially implemented in the newer version.

And the newly introduced bill does have some notable revisions versus the draft document.

For instance, the bill still includes a 10% national tax on all marijuana products for the first two years if the bill becomes law, and that tax would gradually ramp up to 25%, a provision staunchly opposed by marijuana trade groups.

But in the newer version, that tax rate will only apply to “larger cannabis businesses,” while the excise tax for “small and mid-sized producers” would be only half the rate, starting at 5% and ramping up to 12.5% over five years, according to a synopsis of the bill from Schumer’s office.

Impact on cannabis stocks

Pablo Zuanic, an investment analyst at New York-based Cantor Fitzgerald, thinks the revised bill is “bullish for cannabis stocks,” especially considering values have been depressed, “the recent rally notwithstanding.”

“If Sen. Schumer’s cannabis reform bill (as filed this morning) were to be passed by Congress, it would be a watershed event for U.S. cannabis stocks,” Zuanic wrote in a research note Thursday morning.

“But we are doubtful it will have 60 votes in the Senate, so we will closely monitor his comments and those of Republicans in the coming days,” including the willingness of the bill sponsors to compromise, Zuanic wrote, echoing a long-held analysis from Congressional observers.

Zuanic added that he sees the bill as more than just midterm “election posturing” and instead a serious effort to develop what could be historic legislation.

Investors initially seemed indifferent to Thursday’s development, in sharp contrast to soaring prices when Schumer in early 2021 announced his plan to introduce a sweeping marijuana reform bill.

An exchange-traded fund that tracks U.S. multistate operators – AdvisorShares Pure US Cannabis ETF – declined slightly Thursday morning, before finishing strong and closing at $12.65 a share, up 3.6% for the day.

The cannabis ETF, which trades on the New York Stock Exchange Arca as MSOS, has plummeted from $26 a share at the beginning of the year.

Will anything happen this year?

The introduction of Schumer’s bill could spur more political wrangling behind the scenes to get some type of cannabis reform passed by the end of the year, several industry experts said, even if the majority leader’s bill itself winds up being tabled.

Meyer, of the Global Alliance for Cannabis Commerce, noted that a large number of bills approved by Congress in the past decade have been accomplished in the month-and-a-half lame duck session that follows the midterm elections in November but which precedes the next Congress, which convenes in January.

That window often leads to a lot of compromise deals, Meyer said, and the SAFE Banking Act could be one such deal, riding the political momentum that Schumer just created with his bill.

“It’s entirely possible. It depends on what happens in the next couple weeks,” Meyer said.

“I wouldn’t be surprised if we see something little float through where there’s almost no objection. Maybe a medical marijuana research bill. And then if that occurs, there’s a real chance you could get a SAFE Banking compromise package.”

Amber Littlejohn, the executive director of the Minority Cannabis Business Association, also said there are signals within the CAOA text that Democratic senators like Cory Booker – who have objected to SAFE Banking being passed before marijuana-related criminal justice reforms are enacted – have realized how important access to capital is for small and minority marijuana companies.

That, she said, gives her hope that a compromise on SAFE Banking could be reached before the end of the year.

“I’m going to believe in SAFE Banking until the day this session ends,” Littlejohn said. “That affirmation of those challenges really does give me hope again that the Senate understands this is an issue, and one we need to fix, and that we do have a vehicle to fix it this year.”

David Mangone, a spokesman for the National Cannabis Roundtable, agreed with his two counterparts on the CAOA introduction upping the odds for SAFE Banking.

He said the Schumer introduction sets the stage for something – almost anything cannabis-related – to get through Congress.

And he thinks SAFE Banking is near the top of the list of potential victories.

Senate votes key

“It still comes down to the reality of counting votes in the Senate. And right now, when you look at co-sponsorship, SAFE Banking is one of those bills where it’s very conceivable that you could overcome a Republican filibuster (in the Senate). There are nine (GOP) senators on the standalone bill,” Mangone observed.

And, he noted, Schumer and his team didn’t just pay lip service to the CAOA with soliciting feedback, which he said is evident just from how it was amended between last year and this week.

“Just from page count alone, it does show that they sincerely took a lot of feedback, and incorporated it… (the bill) jumped from about 150 pages to almost 300,” Mangone said.

“To me, that shows they are serious about getting some form of reform done, because if they weren’t, we would have seen the exact same bill introduced. Not many changes, just a new title slapped on it.”

Steve Hawkins, the CEO of the U.S. Cannabis Council, said he wouldn’t be surprised to see a package of marijuana policy issues approved that combines marijuana research, federal criminal record expungement and SAFE Banking.

“We very well may see a package of all three pass Congress later in the year,” Hawkins said.

Source: https://mjbizdaily.com/schumer-marijuana-legalization-bill-finally-introduced-in-senate/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News